Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Caraway

Explore full profile

invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy

Cambridge, United StatesFounded 2018Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2023
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Caraway and the history behind them.

About Caraway

Caraway Therapeutics is an emerging biopharmaceutical company focused on developing novel treatments for debilitating neurodegenerative diseases. The company is pioneering the use of cellular recycling processes, known as autophagy, to clear toxic materials and defective cellular components from neurons. This innovative approach aims to preserve neuron function and slow disease progression. Caraway Therapeutics primarily serves patients suffering from neurodegenerative conditions, a market characterized by high unmet medical needs and significant demand for effective therapies. The company's business model revolves around rigorous scientific research and development, leveraging genetically defined targets to identify potential therapeutic candidates. Revenue is generated through research grants, partnerships, and eventual commercialization of successful treatments.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2018
Headquarters
Cambridge, United States
Employees
4
Open positions
None listed
Dealroom signal
25.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Pay Per Result, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
b2b
Links
WebsiteLinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Nov 2023 $610M $610M Merck & Co. ↗
SERIES A✓Equity / VC Nov 2018 $23M $92M Mayo Clinic · Abbvie Biotech Ventures · MRL Ventures · Amgen Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Caraway website traffic

Latest recorded traffic for Caraway is 280 monthly website visits, down 54.1% over the last three months. Caraway's team declined 82.6% over the past year.

Latest monthly visits280 3-month web change-54.1% 1-year team growth-82.6%
Monthly website visitsNov 2023–Sep 2024
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
GreyWolf TherapeuticsAntigen modulation therapies for oncology and autoimmune diseases Milton, United Kingdom Operational 57 $121M $200M
Proton Partners InternationalVanguard of advancing cancer care, building a series of oncology centres known as the Rutherford Cancer Centres | Proton beam therapy/radiotherapy Newport, United Kingdom Operational
OmniomeDeveloper of an innovative new DNA sequencing platform San Diego, United States Acquired
EMOSISDevelops and provides products aim at providing a comprehensive blood tests panel for the bioclinical investigation of thrombosis-induced or thrombosis-complicated diseases Illkirch, France Operational
Xintela ABA biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage Burlövs kommun, Sweden Operational
AnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market Dongcheng District, China Operational
PamGeneOffering kinase activity & nuclear receptor solutions in academic research & pharma partnerships 's-Hertogenbosch, Netherlands Operational
ISA PharmaceuticalsDeveloping rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections Leiden, Netherlands Closed
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Abbvie Biotech Ventures
  • MRL Ventures
  • Mayo Clinic
  • Amgen Ventures
  • Alexandria Venture Investments

Other known investors2 additional known investors

  • Merck & Co.
  • SV Health Investors

Talent

Book a demo to see the people
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Caraway on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Caraway’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.